Latest Report Overview for Boston Scientific Corp ($BSX)
AI-powered analysis of Boston Scientific Corp (BSX) stock based on Q2 2026 financial data.
Latest Report Overview
Boston Scientific Corp (BSX) reported For the quarterly period ended June 30, 2026 (Issuer fiscal Q2 FY2026) revenue of $5,442 million with diluted EPS of $0.61 and net income of $907 million. Operating margin was 21.8%, and free cash flow was $1,280 million for the period. Management commentary continues to emphasize the integration of key recent acquisitions and the acceleration of R&D investments, which reached $554 million for the quarter. The company is navigating a complex regulatory environment while capitalizing on procedure volume recovery in key global markets. Operational discipline remained a focal point, as indicated by an operating margin of 21.8%, reflecting effective management of cost structures despite inflationary pressures. The balance sheet reflects a strategic commitment to growth through inorganic means, supported by $1,475 million in operating cash flow. While debt levels remain elevated at $12.6 billion, the company maintains sufficient liquidity to support its capital allocation strategy, which includes aggressive R&D reinvestment and selected share repurchases, with $1,995 million in common stock repurchased during the quarter.
Key Takeaways for Boston Scientific Corp
- Reported Q2 2026 revenue of $5.44 billion, representing 7.5% YoY growth, driven by strength in core cardiovascular and med-surg franchises.
- Operating margin of 21.8% demonstrates effective cost discipline amidst heavy R&D investment of $554 million in the period.
- Reported net income of $907 million and diluted EPS of $0.61, reflecting consistent profitability and cash generation.
- Aggressive capital allocation evidenced by $1.995 billion in share repurchases during the quarter, despite significant existing debt loads.
- Debt position remains elevated at $12.6 billion, requiring careful management of liquidity and interest expense coverage moving forward.
- Operating cash flow of $1.475 billion supports continued strategic investment and M&A integration activities.
What Does Boston Scientific Corp Do?
Boston Scientific Corp (BSX) is a global medical technology company that develops, manufactures, and markets devices for use in various medical specialties. Its extensive product portfolio targets areas including Interventional Cardiology (stents, catheters), Peripheral Interventions, Cardiac Rhythm Management, Electrophysiology, Endoscopy, Urology, and Neuromodulation. The company serves hospitals, clinics, and physicians worldwide, positioning itself as a comprehensive solutions provider for minimally invasive medical procedures. By focusing on highly specialized, high-growth markets, BSX aims to improve patient outcomes while reducing the total cost of care. Their model relies on continuous innovation, regular product launches, and deep integration with clinical workflows to maintain market leadership.